DXCM - FDA Approval For DexCom's Stelo Opens Continuous Glucose Monitoring To Masses Analyst Expects Competitive Pricing Against Abbott's | Benzinga
Tuesday, the FDA approved DexCom Inc’s (NASDAQ:DXCM) Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM).
The Dexcom Stelo Glucose Biosensor System is an integrated CGM (iCGM) intended for anyone 18 years and older who does not use insulin.
William Blair states that although initial pricing details for Stelo are undisclosed, it is anticipated to be competitive with Abbott Laboratories (NYSE:ABT) current cash-pay price of approximately $80 per month.
DexCom, historically priced slightly higher than Abbott, is estimated at $90 per month, with potential cost reductions for patients through HSA benefits based on their tax bracket.
The analyst notes the FDA’s suggestion of requiring ...